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ABSTRACT	 	A	 simple,	 rapid	 and	 precise	method	was	 developed	 for	 the	 quantitative	 simultaneous	 determination	 of	Omeprazole	and	Domperidone	in	combined	pharmaceutical-dosage	forms.	The	method	was	based	on	UV-Spectrophotometric	determination	of	two	drugs,	using	simultaneous	equation	method.	It	involves	absorb-ance	measurement	at	291	nm	(λmax	of	Omeprazole)	and	289	nm	(λmax	of	Domperidone)	in	Methanol:	Ac-etonitrile	(30:70	v/v).	For	UV	Spectrophotometric	method,	linearity	was	obtained	in	concentration	range	of	1-15	µg/ml	for	Domperidone	and	1-50	µg/ml	for	Omeprazole	respectively,	with	regression	0.999	and	0.999	for	Domperidone	and	Omeprazole	respectively.	Recovery	was	in	the	range	of	99	-103%;	the	value	of	stand-ard	deviation	and	%R.S.D	were	found	to	be	<	2	%;	shows	the	high	precision	of	the	method.,	in	accordance	with	ICH	guidelines.	The	method	has	been	successively	applied	to	pharmaceutical	formulation	and	was	val-idated	according	to	ICH	guidelines.	
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INTRODUCTION	Development	 of	 the	 simple	 and	 reproducible	analytical	methods	for	estimation	of	multicomponent	drugs	is	very	important	part	of	quality	control	and	for	social	 awareness	which	was	 established	 in	 present	work.	
Omeprazole[1]	 (PP),	 5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-benzimidazole	,	is	a	selective	and	long-acting	proton-pump	 inhibitor	 used	 for	 treatment	 of	 acid-related	gastrointestinal	disorders[2].	
 
Figure 1: Omeprazole	Domperidone[1]	 5-Chloro-1-[1-[3-(2-oxo-2,	 3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1,	 3-Dihydro-2H-benzimidazol-2-onehydrogen	(Z)-butenedioate	 is	 a	 synthetic	 benzimidazole	compound	 that	 acts	 as	 a	 dopamine	 receptor	antagonist.			
 
Figure 2: Domperidone	
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Domperidone	is	an	antiemetic	agent[3].	Domperidone	is	 a	 butyrophenone	 derivative	 and	 is	 a	 potent	 D2	receptor	 antagonist	 that	 does	 not	 enter	 the	 CNS	(Blood	 Brain	 Barrier)	 to	 a	 significant	extent.		However,	it	inhibits	D2	Receptors	in	the	CTZ	(Chemo	Trigger	 Zone)	 and	 causes	 prolactin	 release	from	 the	 anterior	 pituitary2.		 The	 combination	 of	Omeprazole	and	Domperidone	was	very	useful	in	the	treatment	 of	 major	 antiulcer	 disorder,	 generalized	gastroesophageal	 reflux	 disorder.	 The	 validation	 of	method	was	carried	out	as	per	ICH	guidelines.																																															
MATERIALS	AND	METHODS	
Chemical	 and	 Reagents:	 Domperidone	 and	Omeprazole	were	kindly	gifted	by	Nutech	Biosciences	Pvt	 Ltd,	 Hyderabad	 certified	 to	 contain	 99.9%	 and	99.6%	 purity	 respectively.	 The	 drugs	 were	 used	without	further	purification.	All	the	solvents	used	in	analysis	were	of	HPLC	grade.	Ome-D	capsules	(label	claim	10	mg	Domperidone	and	20	mg	Omeprazole)	of	Aristo	pharma	was	used	in	analysis.	
UV-spectrophotometry:	 UV-	 spectrophotometer	(Analytical	 Technologies-1800)	 with	 spectral	bandwidth	of	2	nm	and	10	mm	matched	quartz	cells	was	used.	
Preparation	 of	 standard	 stock	 solutions:	 Pure	drug	samples	of	Domperidone	and	Omeprazole	were	dissolved	separately	in	methanol	so	as	to	give	several	dilutions	of	standard	in	the	concentration	range	of	1-15	mcg/ml	 for	 Domperidone	 and	 1-50	mcg/ml	 for	Omeprazole	respectively.	All	dilutions	were	scanned	in	the	wavelength	range	of	190-400	nm.	Simultaneous	 equation	 method	 based	 on	 the	principle	 that,	 the	 total	 absorbance	 of	 the	components	 in	 a	 mixture	 is	 the	 sum	 of	 individual	absorbance,	 two	 wavelength	 selected	 to	 frame	 the	simultaneous	equation	method	were	at	289	and	291	nm.	 For	 calibration	 curves,	 stock	 solutions	 of	Domperidone	and	Omeprazole	 in	 the	 concentration	range	 of	 1-15	 mcg/ml	 and	 1-50	 mcg/ml.	 The	absorbance	 of	 Domperidone	 and	 Omeprazole	 were	measured	at	289	nm	and	291	nm,	calibration	curves	were	plotted.	The	absorptivity’s	of	both	the	drugs	at	both	the	wavelengths	were	determined	
Table 1:  Absorptivity of Omeprazole and Domperi-
done capsules 
Name	 Absorptivity	at		289	nm	
Absorptivity	at	
291	nm	Ome	Dom	capsule	 ax1=0.03680233	ay1=0.02731832	A1=1.092	 ax2=0.0371652	ay2=0.0257032	A2=1.084	Cx(Ome)	 =	 A1*ay2-A2*ay1/	 (ax2*ay1)-(ax1*ay2)																Cy(dom)		=A2*ax1-A1*ax2/	(ax2*ay1)-(ax1*ay2)	
Recovery	studies:	To	check	the	accuracy	of	sample	by	 the	 developed	 methods	 and	 to	 study	 the	interference	 of	 formulation	 additives,	 analytical	
recovery	experiments	were	carried	out	by	standard	addition	method	at	80,	100	and	120	%	level.	From	the	total	amount	of	drug	found,	the	percentage	recovery	was	calculated.	The	results	are	reported	as	below.	
 
Figure 3: Overlain Spectra of Omeprazole & Domperi-
done	
Table 2: Analysis data of Capsule formulations 
Parameter	 UV-spectrophotometry	OME	 DOM	Label	claim	 20 10	Drug	found	 20.28 9.95	
% Accuracy	 98-102 98-102	
% Recovery ± RSD	 101.4±0.254 99.5±0.213 
UV	Validation		
Linearity	 &	 Range:	 The	 linearity	 of	 calibration	curves	(Absorbance	Vs.	concentration)	in	pure	drug	solution	was	checked	over	the	concentration	ranges	of	about	1-50	µg/ml	and	1-15	µg/ml	for	Omeprazole	and	Domperidone.	
 
Figure 4: Calibration curve of Omeprazole 
 
Figure 5: Calibration curve of Domperidone 
Accuracy:	Accuracy	of	 the	method	was	determined	by	 recovery	 experiments.	 To	 the	 formulation,	 the	reference	 standards	 of	 the	 drug	were	 added	 at	 the	level	of	80%,	100%,	120%.	The	recovery	studies	were	carried	out	three	times	and	the	percentage	recovery	was	found	to	be	within	the	range	of	98-102	
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Precision:	 The	 data	 for	 Intraday	 and	 Inter-day	precision	studies	at	three	different	concentrations	in	the	linearity	range.	The	%RSD	values	for	Intraday	and	Interday	 precision	 were	 <	 2%,	 indicating	 that	 the	method	was	sufficiently	precise.		
LOD	 &	 LOQ:	 The	 LOD	 &	 LOQ	 were	 separately	determined	 based	 on	 the	 standard	 deviation	 of	 Y-intercept	 of	 the	 calibration	 curve.	 The	 standard	deviation	 of	 the	 Y-	intercept	and	the	slope	of	the	calibration	curves	were	used	 to	 calculate	 the	 LOD	 and	 LOQ	 by	 using	 the	equations,	 3.3*std.dev/slope	 for	 LOD,	10*std.dev/slope	for	LOQ.			
Table 3: LOD and LOQ of Omeprazole, Domperidone 
	 Omeprazole	 Domperidone	LOD	 0.264	µg/ml	 0.331	µg/ml	LOQ	 0.816	µg/ml	 1.123	µg/ml	
CONCLUSION	The	method	described	for	simultaneous	estimation	of	Omeprazole	 and	 Domperidone	 are	 found	 to	 be	simple,	 sensitive,	 accurate,	 precise,	 economical	 and	rapid.	Hence	method	could	be	successfully	employed	for	routine	analysis	of	Omeprazole	and	Domperidone	in	their	combined	Pharmaceutical	dosage	forms.	
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